Factor VIII inhibitor: Difference between revisions
No edit summary |
(Text replacement - "==References== " to "==References== <references/> ") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
{{Increased bleeding DDX}} | {{Increased bleeding DDX}} | ||
== | ==Evaluation== | ||
*PTT does not correct after mixing | *PTT does not correct after mixing | ||
==Management== | ==Management== | ||
*Bleeding | *Bleeding | ||
** | **Give high dose Factor VII, prothrombin, or recombinant factor VIIa | ||
==Disposition== | ==Disposition== | ||
| Line 19: | Line 19: | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] | ||
Latest revision as of 01:13, 24 July 2017
Background
Clinical Features
Differential Diagnosis
Coagulopathy
Platelet Related
- Too few
- Nonfunctional
Factor Related
- Acquired (Drug Related)
- Warfarin (Coumadin)
- Unfractionated heparin
- Low molecular weight heparin (i.e. enoxaparin (Lovenox), dalteparin)
- Factor Xa Inhibitors (e.g. rivaroxaban, apixaban, fondaparinux, edoxaban)
- Direct thrombin inhibitors (e.g. dabigatran, argatroban, bivalirudin)
- Illness induced
- Genetic
Evaluation
- PTT does not correct after mixing
Management
- Bleeding
- Give high dose Factor VII, prothrombin, or recombinant factor VIIa